Evaluation of delayed additional fdg pet imaging in patients with pancreatic tumour

Nuclear Medicine Communications

Volumn 26, Issue 10, 2005, Pages 895-901

  Nishiyama, Yoshihiro ^a   Yamamoto, Yuka ^b   Monden, Toshihide ^b   Sasakawa, Yasuhiro ^b   Tsutsui, Kunihiko ^b   Wakabayashi, Hisao ^b   Ohkawa, Motoomi ^b  

^a Kagawa University   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Delayed; FDG PET; Pancreatic cancer

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREATITIS; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIODIAGNOSIS; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 26444568648     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200510000-00008     Document Type: Article

References (24)

1. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997; 349:485-489.
2. O’Malley ME, Boland GWL, Wood BJ, Fernandez-del Castillo C, Warshaw AL, Mueller PR. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. Am J Roentgenol 1999; 173:1513-1518.
3. Kalra MK, Maher MM, Sahani DV, Digmurthy S, Saini S. Current status of imaging in pancreatic diseases. J Comput Assist Tomogr 2002; 26:661-675.
4. Castillo CFD, Rattner DW, Warchaw AL. Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br J Surg 1995; 82:1127-1129.
5. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Imamura M, et al. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 1999; 54:248-252.
6. Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, et al. Diagnosis of pancreatic carcinoma: Role of FDG PET. Am J Roentgenol 1998; 171:1565-1570.
7. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999; 40:1784-1791.
8. Frohlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999; 40:250-255.
9. Diederichs CG, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs HJ, et al. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000; 20:109-116.
10. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997; 24:678-682.
11. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25:259-264.
12. Nakamoto Y, Saga T, Ishimori T, Higashi T, Mamede M, Okazaki K, et al. FDG-PET of autoimmuno-related pancreatitis: preliminary results. Eur J Nucl Med 2000; 27:1835-1838.
13. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-1417.
14. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36:1301-1306.
15. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001; 28:696-703.
16. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43:871-875.
17. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003; 44:540-548.
18. 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000; 89:2547-2554.
19. 18F-FDG PET, and hexokinase-II and glucose transporter-I expression in pancreatic cancer. J Nucl Med 2002; 43:173-180.
20. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995; 195:345-352.
21. Orlando LA, Kulasingam SL, Matchar DB. Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther 2004; 20:1063-1070.
22. Waki A, Fujibayashi Y, Yokoyama A. Recent advances in the analysis of the characteristics of tumors on FDG uptake. Nucl Med Biol 1998; 25:589-592.
23. Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) - usefulness and limitations in clinical reality. Ann Nucl Med 2003; 17:261-279.
24. Lowe VJ, Delong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995; 36:883-887.